Polyclonal F(ab’)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency
Summary: We used the recombinant trimeric spike (S) glycoprotein in the prefusion conformation to immunize horses for the production of hyperimmune globulins against SARS-CoV-2. Serum antibody titers measured by ELISA were above 1:106, and the neutralizing antibody titer against authentic virus (WT)...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fd393a9b9edf40629a376603a387320c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:fd393a9b9edf40629a376603a387320c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:fd393a9b9edf40629a376603a387320c2021-11-20T05:09:52ZPolyclonal F(ab’)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency2589-004210.1016/j.isci.2021.103315https://doaj.org/article/fd393a9b9edf40629a376603a387320c2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2589004221012840https://doaj.org/toc/2589-0042Summary: We used the recombinant trimeric spike (S) glycoprotein in the prefusion conformation to immunize horses for the production of hyperimmune globulins against SARS-CoV-2. Serum antibody titers measured by ELISA were above 1:106, and the neutralizing antibody titer against authentic virus (WT) was 1:14,604 (average PRNT90). Plasma from immunized animals was pepsin digested to remove the Fc portion and purified, yielding an F(ab’)2 preparation with PRNT90 titers 150-fold higher than the neutralizing titers in human convalescent plasma. Challenge studies were carried out in hamsters and showed the in vivo ability of equine F(ab’)2 to reduce viral load in the pulmonary tissues and significant clinical improvement determined by weight gain. The neutralization curve by F(ab’)2 was similar against the WT and P.2 variants, but displaced to higher concentrations by 0.39 log units against the P.1 (Gamma) variant. These results support the possibility of using equine F(ab’)2 preparation for the clinical treatment of COVID patients.Luis Eduardo R. CunhaAdilson A. StoletMarcelo A. StrauchVictor A.R. PereiraCarlos H. DumardAndre M.O. GomesFábio L. MonteiroLuiza M. HigaPatrícia N.C. SouzaJuliana G. FonsecaFrancisco E. PontesLeonardo G.R. MeirellesJosé W.M. AlbuquerqueCarolina Q. SacramentoNatalia Fintelman-RodriguesTulio M. LimaRenata G.F. AlvimFederico F. MarsiliMarcella Moreira CaldeiraRussolina B. ZingaliGuilherme A.P. de OliveiraThiago M.L. SouzaAlexandre S. SilvaRodrigo MullerDaniela del Rosário Flores RodriguesLuciana Jesus da CostaArthur Daniel R. AlvesMarcelo Alves PintoAndréa C. OliveiraHerbert L.M. GuedesAmilcar TanuriLeda R. CastilhoJerson L. SilvaElsevierarticleImmunologyEquine immunologyBiological sciencesScienceQENiScience, Vol 24, Iss 11, Pp 103315- (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Immunology Equine immunology Biological sciences Science Q |
| spellingShingle |
Immunology Equine immunology Biological sciences Science Q Luis Eduardo R. Cunha Adilson A. Stolet Marcelo A. Strauch Victor A.R. Pereira Carlos H. Dumard Andre M.O. Gomes Fábio L. Monteiro Luiza M. Higa Patrícia N.C. Souza Juliana G. Fonseca Francisco E. Pontes Leonardo G.R. Meirelles José W.M. Albuquerque Carolina Q. Sacramento Natalia Fintelman-Rodrigues Tulio M. Lima Renata G.F. Alvim Federico F. Marsili Marcella Moreira Caldeira Russolina B. Zingali Guilherme A.P. de Oliveira Thiago M.L. Souza Alexandre S. Silva Rodrigo Muller Daniela del Rosário Flores Rodrigues Luciana Jesus da Costa Arthur Daniel R. Alves Marcelo Alves Pinto Andréa C. Oliveira Herbert L.M. Guedes Amilcar Tanuri Leda R. Castilho Jerson L. Silva Polyclonal F(ab’)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency |
| description |
Summary: We used the recombinant trimeric spike (S) glycoprotein in the prefusion conformation to immunize horses for the production of hyperimmune globulins against SARS-CoV-2. Serum antibody titers measured by ELISA were above 1:106, and the neutralizing antibody titer against authentic virus (WT) was 1:14,604 (average PRNT90). Plasma from immunized animals was pepsin digested to remove the Fc portion and purified, yielding an F(ab’)2 preparation with PRNT90 titers 150-fold higher than the neutralizing titers in human convalescent plasma. Challenge studies were carried out in hamsters and showed the in vivo ability of equine F(ab’)2 to reduce viral load in the pulmonary tissues and significant clinical improvement determined by weight gain. The neutralization curve by F(ab’)2 was similar against the WT and P.2 variants, but displaced to higher concentrations by 0.39 log units against the P.1 (Gamma) variant. These results support the possibility of using equine F(ab’)2 preparation for the clinical treatment of COVID patients. |
| format |
article |
| author |
Luis Eduardo R. Cunha Adilson A. Stolet Marcelo A. Strauch Victor A.R. Pereira Carlos H. Dumard Andre M.O. Gomes Fábio L. Monteiro Luiza M. Higa Patrícia N.C. Souza Juliana G. Fonseca Francisco E. Pontes Leonardo G.R. Meirelles José W.M. Albuquerque Carolina Q. Sacramento Natalia Fintelman-Rodrigues Tulio M. Lima Renata G.F. Alvim Federico F. Marsili Marcella Moreira Caldeira Russolina B. Zingali Guilherme A.P. de Oliveira Thiago M.L. Souza Alexandre S. Silva Rodrigo Muller Daniela del Rosário Flores Rodrigues Luciana Jesus da Costa Arthur Daniel R. Alves Marcelo Alves Pinto Andréa C. Oliveira Herbert L.M. Guedes Amilcar Tanuri Leda R. Castilho Jerson L. Silva |
| author_facet |
Luis Eduardo R. Cunha Adilson A. Stolet Marcelo A. Strauch Victor A.R. Pereira Carlos H. Dumard Andre M.O. Gomes Fábio L. Monteiro Luiza M. Higa Patrícia N.C. Souza Juliana G. Fonseca Francisco E. Pontes Leonardo G.R. Meirelles José W.M. Albuquerque Carolina Q. Sacramento Natalia Fintelman-Rodrigues Tulio M. Lima Renata G.F. Alvim Federico F. Marsili Marcella Moreira Caldeira Russolina B. Zingali Guilherme A.P. de Oliveira Thiago M.L. Souza Alexandre S. Silva Rodrigo Muller Daniela del Rosário Flores Rodrigues Luciana Jesus da Costa Arthur Daniel R. Alves Marcelo Alves Pinto Andréa C. Oliveira Herbert L.M. Guedes Amilcar Tanuri Leda R. Castilho Jerson L. Silva |
| author_sort |
Luis Eduardo R. Cunha |
| title |
Polyclonal F(ab’)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency |
| title_short |
Polyclonal F(ab’)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency |
| title_full |
Polyclonal F(ab’)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency |
| title_fullStr |
Polyclonal F(ab’)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency |
| title_full_unstemmed |
Polyclonal F(ab’)2 fragments of equine antibodies raised against the spike protein neutralize SARS-CoV-2 variants with high potency |
| title_sort |
polyclonal f(ab’)2 fragments of equine antibodies raised against the spike protein neutralize sars-cov-2 variants with high potency |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/fd393a9b9edf40629a376603a387320c |
| work_keys_str_mv |
AT luiseduardorcunha polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT adilsonastolet polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT marceloastrauch polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT victorarpereira polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT carloshdumard polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT andremogomes polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT fabiolmonteiro polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT luizamhiga polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT patriciancsouza polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT julianagfonseca polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT franciscoepontes polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT leonardogrmeirelles polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT josewmalbuquerque polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT carolinaqsacramento polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT nataliafintelmanrodrigues polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT tuliomlima polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT renatagfalvim polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT federicofmarsili polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT marcellamoreiracaldeira polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT russolinabzingali polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT guilhermeapdeoliveira polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT thiagomlsouza polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT alexandressilva polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT rodrigomuller polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT danieladelrosariofloresrodrigues polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT lucianajesusdacosta polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT arthurdanielralves polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT marceloalvespinto polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT andreacoliveira polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT herbertlmguedes polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT amilcartanuri polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT ledarcastilho polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency AT jersonlsilva polyclonalfab2fragmentsofequineantibodiesraisedagainstthespikeproteinneutralizesarscov2variantswithhighpotency |
| _version_ |
1718419578368819200 |